Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series.
Gómez-Ibáñez A, Serratosa JM, Guillamón E, Garcés M, Giráldez BG, Toledo M, Salas-Puig J, López-González FJ, Rodríguez-Uranga J, Castillo A, Mauri JA, Camacho JL, López-Gomáriz E, Giner P, Torres N, Palau J, Molins A, Villanueva V. Gómez-Ibáñez A, et al. Seizure. 2017 May;48:53-56. doi: 10.1016/j.seizure.2017.04.003. Epub 2017 Apr 7. Seizure. 2017. PMID: 28419947 Free article.
Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide.
Villanueva V, López FJ, Serratosa JM, González-Giraldez B, Campos D, Molins A, Rodriguez Uranga J, Mauri JA, Salas-Puig J, Toledo M, Sánchez-Alvarez JC, Moreno A, Serrano-Castro PJ, Saiz-Diaz RA, González de la Aleja J, de la Peña P, Asensio M. Villanueva V, et al. Epilepsy Behav. 2013 Nov;29(2):349-56. doi: 10.1016/j.yebeh.2013.07.024. Epub 2013 Aug 30. Epilepsy Behav. 2013. PMID: 23999191
Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study.
Villanueva V, Serratosa JM, Guillamón E, Garcés M, Giráldez BG, Toledo M, Salas-Puig J, López González FJ, Flores J, Rodríguez-Uranga J, Castillo A, Mauri JA, Camacho JL, López-Gomáriz E, Giner P, Torres N, Palau J, Molins A. Villanueva V, et al. Epilepsy Res. 2014 Sep;108(7):1243-52. doi: 10.1016/j.eplepsyres.2014.04.014. Epub 2014 May 14. Epilepsy Res. 2014. PMID: 24908564
Early add-on lacosamide in a real-life setting: results of the REALLY study.
Villanueva V, Garcés M, López-Gomáriz E, Serratosa JM, González-Giráldez B, Parra J, Rodríguez-Uranga J, Toledo M, López González FJ, Bermejo P, Giner P, Castillo A, Molins A, Campos D, Mauri JÁ, Muñoz R, Bonet M, Serrano-Castro P, del Villar A, Saiz-Díaz RA; REALLY Study Group. Villanueva V, et al. Clin Drug Investig. 2015 Feb;35(2):121-31. doi: 10.1007/s40261-014-0255-5. Clin Drug Investig. 2015. PMID: 25488477
Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
Villanueva V, Garcés M, López-González FJ, Rodriguez-Osorio X, Toledo M, Salas-Puig J, González-Cuevas M, Campos D, Serratosa JM, González-Giráldez B, Mauri JA, Camacho JL, Suller A, Carreño M, Gómez JB, Montoya J, Rodríguez-Uranga J, Saiz-Diaz R, González-de la Aleja J, Castillo A, López-Trigo J, Poza JJ, Flores J, Querol R, Ojeda J, Giner P, Molins A, Esteve P, Baiges JJ. Villanueva V, et al. Epilepsy Res. 2016 Oct;126:201-10. doi: 10.1016/j.eplepsyres.2016.08.001. Epub 2016 Aug 4. Epilepsy Res. 2016. PMID: 27521586
EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure.
Villanueva V, Bermejo P, Montoya J, Toledo M, Gómez-Ibáñez A, Garcés M, Vilella L, López-González FJ, Rodriguez-Osorio X, Campos D, Martínez P, Giner P, Zurita J, Rodríguez-Uranga J, Ojeda J, Mauri JA, Camacho JL, Ruiz-Giménez J, Poza JJ, Massot-Tarrús A, Galiano ML, Bonet M. Villanueva V, et al. Acta Neurol Scand. 2017 Sep;136(3):254-264. doi: 10.1111/ane.12720. Epub 2016 Dec 9. Acta Neurol Scand. 2017. PMID: 27935017
Erratum to "Safety, efficacy and outcome-related factors of perampanel over 12months in a real-world setting: The FYDATA study" [Epilepsy Res. 126 (2016) 201-210].
Villanueva V, Garcés M, López-González FJ, Rodriguez-Osorio X, Toledo M, Salas-Puig J, González-Cuevas M, Campos D, Serratosa JM, González-Giráldez B, Mauri JA, Camacho JL, Suller A, Carreño M, Gómez JB, Montoya J, Rodríguez-Uranga J, Saiz-Diaz R, González-de la Aleja J, Castillo A, López-Trigo J, Poza JJ, Flores J, Querol R, Ojeda J, Giner P, Molins A, Esteve P, Baigesr JJ. Villanueva V, et al. Epilepsy Res. 2017 Jan;129:174-175. doi: 10.1016/j.eplepsyres.2016.12.005. Epub 2016 Dec 22. Epilepsy Res. 2017. PMID: 28017504 No abstract available.
Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study.
Villanueva V, Montoya J, Castillo A, Mauri-Llerda JÁ, Giner P, López-González FJ, Piera A, Villanueva-Hernández P, Bertol V, Garcia-Escrivá A, Garcia-Peñas JJ, Garamendi I, Esteve-Belloch P, Baiges-Octavio JJ, Miró J, Falip M, Garcés M, Gómez A, Gil-López FJ, Carreño M, Rodriguez-Uranga JJ, Campos D, Bonet M, Querol R, Molins A, Tortosa D, Salas-Puig J. Villanueva V, et al. Epilepsia. 2018 Sep;59(9):1740-1752. doi: 10.1111/epi.14522. Epub 2018 Jul 31. Epilepsia. 2018. PMID: 30062784
56 results